Why Charles River Laboratories International, Inc. (CRL) stock moved
Charles River Laboratories International, Inc. (CRL) shares fell 1.3% to $278.06 as of September 20, 2026, a modest decline from the prior close of $281.67. BestStocks flagged the session as a major change for CRL. Below, we break down what changed for CRL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
CRL fell 1.3% to $278.06
Charles River Laboratories International, Inc. moved -2.24% intraday from $278.26 to $272.03. Charles River Laboratories (NYSE: CRL) stock is down 2.2% today, trading at $272.15 after touching an intraday low of $267.27. ## Charles River Laboratories Intrtnl, Inc. (CRL) $272.15 -2.20% today As of Sep 14, 3:51 PM EDT • Disclaimer 10:00 AM 12:00 PM 2:00 PM 270 275 Prev close $278.26 Sep 14, 2026 9:35 AM - 3:51 PM 1D 5D 1M 6M YTD 1Y 5Y Max| Open 278.27 | Mkt cap $12.99B USD | 52-wk high 303.31 | | High 279.64 | P/E ratio- | 52-wk low 144.26 | | Low 267.27 | Div yield- | The market's reaction follows the company's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference today. While the leadership team, led by new CEO Birgit and CFO Glenn, highlighted that the company is transitioning away from a long slowdown toward a period of stabilization, investors are reacting to key notes of caution: - Gradual and Uneven Recovery: Management explicitly noted that the business turnaround will be gradual and uneven rather than a swift, uniform recovery across all sectors. - Lagging Segment Performance: The Research Models and Services (RMS) segment continues to deliver mixed results and is still projected to experience a low single-digit percentage decline through the re Monitor for follow-through at the close.
What it means for Charles River Laboratories International, Inc. investors
For Charles River Laboratories International, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Charles River Laboratories International, Inc. (CRL) moved +3.50% from $267.62 to $277.00 on 2026-08-10, reaching a new 30-day high; Charles River Laboratories International, Inc. (CRL) moved +2.28% from $261.53 to $267.49 on 2026-08-07. Weighing against that: Negative session, down 1.3%; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $282.36, implying +1.5% upside from $278.06. Over the past 90 days analysts logged 1 upgrade and 1 downgrade. BestStocks rates the overall signal quality low (45/100). With earnings roughly 45 days out, the next report is the most likely near-term test of the move.
CRL price reaction
CRL last traded at $278.06, down $3.61 (-1.28%) from the previous close of $281.67. The session traded on 1.6× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $272.88 and $298.58, and it currently sits about 20% of the way up that band.
Bullish and bearish analyst opinions on Charles River Laboratories International, Inc. (CRL)
The consensus analyst price target on Charles River Laboratories International, Inc. (CRL) is $282.36, 1.5% above the recent $278.06. Over the past 90 days analysts logged 1 upgrade, 7 maintains, and 1 downgrade. Here is how the bullish and bearish cases on CRL line up.
The bullish case
- Wall Street's consensus price target of $282.36 implies +1.5% upside from $278.06.
- The Street's most bullish target is $330.00 (+18.7%).
- 1 analyst upgrade in the past 90 days, most recently JP Morgan to Overweight (2026-08-06).
- Charles River Laboratories International, Inc. (CRL) moved +3.50% from $267.62 to $277.00 on 2026-08-10, reaching a new 30-day high.
The bearish case
- The most bearish analyst target is $219.00 (-21.2%).
- 1 analyst downgrade in the past 90 days, most recently CLSA to Hold (2026-07-20).
- Negative session, down 1.3%.
- Charles River Laboratories International, Inc. (CRL) moved −2.71% from $267.99 to $260.72 on August 5, 2026.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CRL
Frequently asked questions about CRL
Why did Charles River Laboratories International, Inc. (CRL) stock move?
CRL fell 1.3% to $278.06. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did CRL stock fall?
CRL lost 1.28% ($3.61) versus the prior close of $281.67, last trading at $278.06 on 1.6× average volume.
When is Charles River Laboratories International, Inc.'s next earnings date?
CRL's next earnings report is estimated for 2026-11-04 — about 45 days away.
What is the analyst price target for CRL?
The consensus analyst price target for CRL is $282.36, about 1.5% above the current $278.06. Over the past 90 days, analysts recorded 1 upgrade, 7 maintains, and 1 downgrade.
How BestStocks tracks CRL
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CRL-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for CRL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.